Table 1.
Summary of the MP-12 human volunteer sera samples nAb titers before passive transfer into mice, nAb titers 24 hours after passive transfer, and protection from challenge with pathogenic RVFV ZH501
| Mouse group no. | Animal identification nos. | Sex | Human volunteer serum codes | Human sera RVFV nAb titer1 | nAb titers in mouse sera4 | Days postchallenge animals expired |
|---|---|---|---|---|---|---|
| 2 | 289 | M | – | – | ≤ 5 | Sham-inoculated2 |
| 2 | 290 | F | – | – | ≤ 5 | Sham-inoculated2 |
| 1 | 291 | M | G00043 | ≤ 10 | ≤ 5 | 4 |
| 1 | 292 | M | G00053 | ≤ 10 | ≤ 5 | 6 |
| 1 | 293 | F | G00063 | ≤ 10 | ≤ 5 | 4 |
| 1 | 294 | F | G00073 | ≤ 10 | ≤ 5 | 5 |
| 3 | 295 | M | G2185 | 20 | 5 | Survived |
| 3 | 296 | M | G2185 | 20 | 5 | Survived |
| 3 | 297 | F | G2185 | 20 | 5 | Survived |
| 3 | 298 | F | G2185 | 20 | 5 | 19 |
| 5 | 299 | M | G2156 | 40 | 10 | Survived |
| 5 | 300 | M | G2156 | 40 | 10 | Survived |
| 5 | 301 | F | G2156 | 40 | 20 | Survived |
| 5 | 302 | F | G2156 | 40 | 10 | Survived |
| 7 | 303 | M | G2136 | 80 | 20 | 9 |
| 7 | 304 | M | G2136 | 80 | 20 | Survived |
| 7 | 305 | F | G2136 | 80 | 20 | Survived |
| 7 | 306 | F | G2136 | 80 | 20 | Survived |
F = female; M = male; nAb = neutralizing antibody; RVFV = Rift Valley fever virus.
1 nAb titer of human sera samples before passive transfer to mice.
2 Control mice did not receive serum and were sham inoculated with minimum essential media.
3 Pooled antibody-negative sera samples obtained from human volunteers before receiving the RVFV MP-12 vaccine and the pooled sera was transferred to each of four mice that were challenged with a virulent strain of RVFV to demonstrate that the challenge dose caused a lethal infection of the mice.
4 Reciprocal nAb titer (PRNT80) 24 hours after passive transfer of sera samples to mice.